Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.
Acute Lymphoblastic Leukemia ALL
BIOLOGICAL: Autologous hematopoietic stem cell transplantation combined with CD19-CART
Relapse rate within 2 years, Time Frame: From autologous hematopoietic stem cell transplantation to 2 years after transplantation
Non-relapse mortality, Time Frame: From autologous hematopoietic stem cell transplantation to 2 years after transplantation|Progression-free survival, Time Frame: From autologous hematopoietic stem cell transplantation to 2 years after transplantation|Overall survival rate, Time Frame: From autologous hematopoietic stem cell transplantation to 2 years after transplantation|Incidence of infection, Time Frame: From autologous hematopoietic stem cell transplantation to 2 years after transplantation
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.